Zhongtong Finance App learned that Koronbaute Biotechnology-B (06990) rose more than 4%, as of press time, up 4.41% at HKD 179.8, with a turnover of HKD 19.1182 million.

As for news, Koronbaute Biotechnology announced that the company has received the clinical trial notice of innovative injection drug SKB518, a new drug developed by the company, which was approved by the Drug Evaluation Center of the National Medical Products Administration on June 17. SKB518 injection is an innovative antibody conjugate drug with independent intellectual property rights, developed based on the biological characteristics of target points, using the "OptiDCTM" platform technology, and has demonstrated good efficacy and safety window in preclinical stage, intended to be used for the treatment of advanced solid tumors.

Earlier, Pacific Securities pointed out that the company has 33 innovative projects for major diseases such as tumors, self-immunity, inflammation, metabolism, etc.; 14 projects are advancing clinical research, and multiple clinical trials are multicenter research worldwide; and 19 preclinical stage assets have laid a solid foundation for the company's development.